Treatment-Resistant Depression
Genetic predisposition to neuroticism, insomnia linked to treatment-resistant depression
Genetic predisposition to traits such as depressive affect, neuroticism and insomnia appeared significantly associated with greater risk for treatment-resistant depression, according to a study published in JAMA Psychiatry.
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
VIDEO: ‘New hope on the horizon’ in psychedelic medicine
NEW YORK — In this Healio Video Perspective, Reid Robison, MD, MBA, senior principal investigator at Numinus, a company that conducts clinical trials in psychedelics, discusses promising new treatment options for psychiatric conditions.
J&J seeks FDA approval of esketamine as monotherapy for treatment-resistant depression
Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of esketamine nasal spray as a monotherapy for adults with treatment-resistant depression.
Ketamine may be better option than ECT for less severe treatment-resistant depression
Individuals with moderate to less severe treatment-resistant depression may benefit from treatment with ketamine instead of electroconvulsive therapy, according to research from JAMA Network Open.
Brain stimulation may have distinct near-maximal effective doses across mental disorders
Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.
'A wild west': Patients seek new depression treatments with different mechanisms of action
Patients have become increasingly disillusioned with traditional depression treatments, and the search for new therapies has created some chaos in the field, according to experts.
Liafensine significantly improves treatment-resistant depression in phase 2b trial
Liafensine met all safety and efficacy endpoints and demonstrated significant improvements over placebo as a treatment for treatment-resistant depression in the phase 2b ENLIGHTEN trial, according to a manufacturer-issued press release.
Beckley Psytech reports positive results in trial of treatment-resistant depression drug
More than half of patients with treatment-resistant depression achieved response with a single dose of BPL-003, a benzoate salt formulation of 5-MeO-DMT that is administered intranasally, according to a press release from the manufacturer.
'A Promethean moment': Psychedelics could be prescribed in the next few years
With potential FDA approvals on the horizon, the controversy surrounding psychedelics in clinical practice may soon reach a tipping point, according to experts.